Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02471911 · ClinicalTrials.gov registry record · Phase 1
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02471911 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 22 participants.
The verdict
NCT02471911, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy alone).
Interventions
- DRUG Carboplatin
- DRUG Rituximab
- DRUG Etoposide
- DRUG Ifosfamide
- DRUG KPT-330
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-12-11 |
| Est. Completion | 2021-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02471911
The ClinicalTrials.gov registry entry for NCT02471911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02471911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02471911 about?
NCT02471911 is a clinical study titled "KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma". This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy alone).
What is the current status of trial NCT02471911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2015-12-11. Estimated completion is 2021-10-14.
What interventions are being tested in trial NCT02471911?
The interventions under investigation include: Carboplatin (DRUG), Rituximab (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), KPT-330 (DRUG).
Who is sponsoring clinical trial NCT02471911?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.